|Articles|March 11, 2014
Clinipace Acquisition Pan-Asia CRO, Choice Pharma
Choice Pharma provides Clinipace a significant Pan-Asia footprint
Advertisement
Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements
There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.
This is the 5th acquisition by Clinipace in recent years.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps
2
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges
5